BioCryst Pharmaceuticals Inc (BCRX) — Cash Flow-to-Debt Ratio
BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2026, meaning its operating cash flow of $-62.14 Million could theoretically repay 0% of its total liabilities ($1.02 Billion) in one year. See BioCryst Pharmaceuticals Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioCryst Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1994–2025)
Historical debt coverage capacity for BioCryst Pharmaceuticals Inc across 32 annual periods. For the full cash flow conversion analysis, see BioCryst Pharmaceuticals Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for BioCryst Pharmaceuticals Inc (1994–2025)
Year-by-year debt coverage analysis for BioCryst Pharmaceuticals Inc. Check BCRX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.52x | $329.88 Million | $633.31 Million | ▲ +1067.6% |
| 2024 | -0.05x | $-52.02 Million | $966.35 Million | ▲ +45.0% |
| 2023 | -0.10x | $-95.14 Million | $972.49 Million | ▲ +48.9% |
| 2022 | -0.19x | $-161.85 Million | $844.60 Million | ▲ +6.3% |
| 2021 | -0.20x | $-142.16 Million | $695.14 Million | ▲ +47.2% |
| 2020 | -0.39x | $-137.22 Million | $353.98 Million | ▲ +40.7% |
| 2019 | -0.65x | $-89.58 Million | $137.03 Million | ▲ +31.1% |
| 2018 | -0.95x | $-92.56 Million | $97.61 Million | ▼ -117.8% |
| 2017 | -0.44x | $-41.14 Million | $94.49 Million | ▲ +28.1% |
| 2016 | -0.61x | $-53.44 Million | $88.27 Million | ▼ -254.6% |
| 2015 | -0.17x | $-13.12 Million | $76.83 Million | ▲ +72.9% |
| 2014 | -0.63x | $-38.55 Million | $61.24 Million | ▼ -18.6% |
| 2013 | -0.53x | $-26.53 Million | $49.99 Million | ▲ +17.8% |
| 2012 | -0.65x | $-37.40 Million | $57.89 Million | ▼ -35.0% |
| 2011 | -0.48x | $-32.25 Million | $67.40 Million | ▲ +26.4% |
| 2010 | -0.65x | $-28.55 Million | $43.94 Million | ▼ -124.1% |
| 2009 | -0.29x | $-16.22 Million | $55.92 Million | ▲ +46.8% |
| 2008 | -0.55x | $-20.87 Million | $38.27 Million | ▼ -69.8% |
| 2007 | -0.32x | $-25.00 Million | $77.81 Million | ▲ +0.0% |
| 2006 | -0.32x | $-15.21 Million | $47.33 Million | ▲ +43.8% |
| 2005 | -0.57x | $-23.35 Million | $40.81 Million | ▲ +90.1% |
| 2004 | -5.79x | $-18.15 Million | $3.13 Million | ▲ +14.7% |
| 2003 | -6.79x | $-11.20 Million | $1.65 Million | ▲ +51.3% |
| 2002 | -13.96x | $-16.36 Million | $1.17 Million | ▼ -213.6% |
| 2001 | -4.45x | $-10.16 Million | $2.28 Million | ▼ -1208.9% |
| 2000 | -0.34x | $-3.18 Million | $9.35 Million | ▲ +86.1% |
| 1999 | -2.45x | $-4.90 Million | $2.00 Million | ▲ +18.3% |
| 1998 | -3.00x | $-4.20 Million | $1.40 Million | ▲ +65.0% |
| 1997 | -8.58x | $-10.30 Million | $1.20 Million | ▼ -114.6% |
| 1996 | -4.00x | $-6.80 Million | $1.70 Million | ▲ +6.5% |
| 1995 | -4.28x | $-7.70 Million | $1.80 Million | ▼ -5.3% |
| 1994 | -4.06x | $-6.50 Million | $1.60 Million | — |